GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang AngliKang Pharmaceutical Co Ltd (SZSE:002940) » Definitions » Research & Development

Zhejiang AngliKang Pharmaceutical Co (SZSE:002940) Research & Development : ¥172 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Zhejiang AngliKang Pharmaceutical Co Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Zhejiang AngliKang Pharmaceutical Co's Research & Development for the three months ended in Mar. 2024 was ¥49 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was ¥172 Mil.


Zhejiang AngliKang Pharmaceutical Co Research & Development Historical Data

The historical data trend for Zhejiang AngliKang Pharmaceutical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang AngliKang Pharmaceutical Co Research & Development Chart

Zhejiang AngliKang Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.35 43.88 52.55 112.62 143.37

Zhejiang AngliKang Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.76 33.44 44.35 44.82 49.09

Zhejiang AngliKang Pharmaceutical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥172 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zhejiang AngliKang Pharmaceutical Co  (SZSE:002940) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Zhejiang AngliKang Pharmaceutical Co Research & Development Related Terms

Thank you for viewing the detailed overview of Zhejiang AngliKang Pharmaceutical Co's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang AngliKang Pharmaceutical Co (SZSE:002940) Business Description

Traded in Other Exchanges
N/A
Address
No. 1000, North Luzhou Avenue, Zhejiang Province, Quzhou, CHN, 312400
Zhejiang AngliKang Pharmaceutical Co Ltd is engaged in the manufacturing and sale of pharmaceutical materials, pharmaceutic preparations, and medical empty capsules. The main products offered by the group are cephalosporins antibacterial, angiocarpy drugs and gastrointestinal tract drugs. Geographically, the activities are carried out through Shengzhou, China.
Executives
Pan Xiao Yun Supervisors
Ye Shu Xiang Director
Yang Guo Dong Executives
Xu Ai Fang Supervisors
Wu Zhe Hua Director

Zhejiang AngliKang Pharmaceutical Co (SZSE:002940) Headlines

No Headlines